Search results

Technologies 26

View all

• FeCILL: Targeted Treatment for Severe Fungal Infections
  FeCILL is novel delivery vehicle for antifungal drugs that targets them right to the infection site and reduces harmful side effects in patients with severe fungal infections.
• Ichor: Reversing Aging
  Ichor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health.
• Sugar-to-Fiber Enzyme for Healthier Food
  In collaboration with Kraft Heinz, our sugar-to-fiber product can convert sugar in food products into prebiotic fiber in the human gut, reducing the amount of sugar absorbed into the bloodstream without altering the amount of sugar in existing food product recipes.
• eRapid: Multiplexed Electrochemical Detection of Complex Diseases
  StataDX licensed the eRapid portable electrochemical sensing technology to develop diagnostics for neurological, cardiovascular, and renal diseases with a first focus on building a point-of-care platform for difficult-to-detect neurological disorders.
• CogniXense for Rare Disease Drug Discovery
  Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome.
• Molecular Nucleic Acid Detection Technology to Empower Patients with Self-Testing Capabilities
  This technology provides an innovative molecular diagnostic assay for high-speed, sensitive, and specific detection of nucleic acids from SARS-CoV-2 or other pathogens, performed in a newly devised reusable base unit with pathogen-specific, one-time-use consumables – first prototyped at the Wyss Institute, then transformed into an inexpensive, reliable and manufacturable detection system by 3EO Health.

Collaborations 3

• Biomarker Discovery Laboratory (BDL)
  Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration.
• Kraft Heinz Partnership
  The Kraft Heinz company approached the Wyss Institute for help to achieve its ambitious goal to make its food products healthier, resulting in a novel technology that is ripe for commercialization.
• Brain Targeting Program
  Pre-competitive multi-partner industry collaboration that aims to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain.

News 241

View all

• Press Release
  
  Scientists build tiny biological robots from human cells
  November 30, 2023
• Research Spotlights
  
  Shape-shifting immune cells offer new insights into cancer immunotherapy
  November 17, 2023
• Awards
  
  Wyss Institute at Harvard University wins BARDA contract to leverage human Organ Chips to advance knowledge and drug discovery for broad range of health security threats
  October 18, 2023

Multimedia 79

View all

• 

  Video/Animation
  World of OMICs w/ David Walt & Mike Snyder – BIOS Roundtable
  This is a roundtable discussion on the world of OMICs with Wyss Core Faculty member David Walt and Mike Snyder of Stanford University presented by BIOS. David Walt is a Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School, a Professor of Pathology at Brigham and Women’s Hospital, a Core Faculty member at...

• 

  Video/Animation
  Genetic & Cellular Engineering w/ David Schaffer & Samir Mitragotri – BIOS Roundtable
  Samir Mitragotri is a Core Faculty member at the Wyss Institute and the Hiller Professor of Bioengineering & Hansjorg Wyss Professor of Biologically Inspired Engineering at Harvard SEAS. David Schaffer is Professor at UC Berkeley & Director at BBH. The two discuss Genetic and Cellular Engineering, with a focus on delivery challenges.

• 

  Video/Animation
  Bridging science, engineering, and art: from mechanobiology to Human Organs-on-Chips
  In this Marsilius Lecture, Wyss Founding Director Don Ingber shares his personal path from a serendipitous experience in an undergraduate art class that led to his discovery of how living cells are constructed using “tensegrity” architecture and how this contributed to the birth of the field of Mechanobiology to his more recent work on human...

• 

  Video/Animation
  Novel Model Organisms w/ Don Ingber & Hans Clevers – BIOS Roundtable
  Don Ingber – Founding Director at Wyss Institute Hans Clevers – Head of Pharma Research & Development (pRED) at Roche Hear about the evolution of humanized models and their potential applications in drug development, personalized medicine, and more. Ingber and Clevers share their scientific experiences and expertise. They also discuss misconceptions surrounding the application of...

• 

  Video/Animation
  How do we make safer and more effective drugs?
  Wyss researchers are using an ever-growing number of human tissue-mimicking Organ Chips to improve and accelerate the drug development process for a wide number of unmet diseases – and understand what causes them to erupt. More recently, they added a human Vagina Chip and personalized Barrett’s esophagus Chip to their arsenal, and created in vitro...

• 

  Video/Animation
  How can we get diagnostics to patients faster?
  The Wyss Diagnostics Accelerator (DxA) is an initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs. Credit: Wyss Institute at Harvard University